Sysmex Co. (OTCMKTS:SSMXY) Sees Significant Drop in Short Interest

Sysmex Co. (OTCMKTS:SSMXY) was the target of a large decrease in short interest in the month of April. As of April 15th, there was short interest totalling 2,400 shares, a decrease of 63.1% from the March 31st total of 6,500 shares. Based on an average trading volume of 90,400 shares, the short-interest ratio is currently 0.0 days.

Sysmex Stock Performance

SSMXY stock traded down $0.26 during trading hours on Friday, hitting $15.85. 76,508 shares of the stock were exchanged, compared to its average volume of 56,791. The company has a current ratio of 3.10, a quick ratio of 2.27 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $9.98 billion, a P/E ratio of 31.79 and a beta of 0.66. The company has a 50-day simple moving average of $17.44 and a two-hundred day simple moving average of $17.51. Sysmex has a 12 month low of $15.02 and a 12 month high of $36.57.

Sysmex (OTCMKTS:SSMXY) last posted its earnings results on Friday, February 9th. The company reported $0.13 EPS for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.03). Sysmex had a return on equity of 11.15% and a net margin of 10.25%. The firm had revenue of $770.84 million during the quarter. On average, analysts forecast that Sysmex will post 0.53 earnings per share for the current fiscal year.

About Sysmex

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.